Potentiation of antitumor activity of bleomycin towards solid tumors in mice by Bacillus thuringiensis subsp. israelensis toxin.
We previously reported that a 25-kDa Bacillus thuringiensis subsp. israelensis (BTI) toxin is cytotoxic to cultured tumor cells and can also potentiate the cytotoxic effect of some antitumor agents in vitro. In this study, we examined the in vivo effect of BTI toxin on the potentiation of antitumor activity of bleomycin (BLM) against solid tumor-bearing mice. Three tumor cell lines, Ehrlich carcinoma, B16 melanoma and Meth A fibrosarcoma, were employed. It was shown that dose of BTI toxin, ineffective alone, potentiated the antitumor activity of BLM when used in combination.
Yokoyama
Y
Y
Laboratory of Bioscience, Toa Gosei Chemical Industry, Nagoya, Japan.
Ohmori
I
I
Kohda
K
K
Kawazoe
Y
Y
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001413:Bacillus thuringiensis; D000083722:Bacillus thuringiensis Toxins; D001426:Bacterial Proteins / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D001427:Bacterial Toxins / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D004357:Drug Synergism; D004731:Endotoxins; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy*; D006460:Hemolysin Proteins; D008546:Melanoma, Experimental / Q000188:drug therapy*; D051379:Mice; D008813:Mice, Inbred ICR; D008815:Mice, Inbred Strains; D012513:Sarcoma, Experimental / Q000188:drug therapy*
D000083722:Bacillus thuringiensis Toxins; D001426:Bacterial Proteins; D001427:Bacterial Toxins; D004731:Endotoxins; D006460:Hemolysin Proteins; C030956:insecticidal crystal protein, Bacillus Thuringiensis; D001761:Bleomycin